ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares

Posted by Geri Gentry on Jun 9th, 2026

ResMed Inc. (NYSE:RMD – Get Free Report) CEO Michael Farrell sold 4,991 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $193.96, for a total transaction of $968,054.36. Following the completion of the sale, the chief executive officer directly owned 466,256 shares of the company’s stock, valued at approximately $90,435,013.76. This trade represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Trading Up 1.7%

ResMed stock traded up $3.32 during trading hours on Tuesday, hitting $196.46. The company had a trading volume of 483,971 shares, compared to its average volume of 1,211,436. The firm has a market cap of $28.50 billion, a P/E ratio of 18.94, a P/E/G ratio of 1.25 and a beta of 0.80. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. ResMed Inc. has a 1 year low of $180.26 and a 1 year high of $293.81. The company has a 50-day moving average price of $212.53 and a two-hundred day moving average price of $236.78.

ResMed (NYSE:RMD – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.79 by $0.07. The company had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.37 EPS. On average, sell-side analysts anticipate that ResMed Inc. will post 11.13 earnings per share for the current year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, May 14th. ResMed’s payout ratio is 23.14%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on RMD shares. Robert W. Baird set a $225.00 price target on shares of ResMed in a report on Friday, May 1st. Wells Fargo & Company reduced their price target on shares of ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a report on Friday, May 1st. KeyCorp reduced their price target on shares of ResMed from $302.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, April 27th. Evercore set a $255.00 price target on shares of ResMed and gave the company an “outperform” rating in a report on Monday, April 13th. Finally, Citigroup reduced their price target on shares of ResMed from $345.00 to $340.00 and set a “buy” rating for the company in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $286.18.

Get Our Latest Analysis on RMD

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RMD. Jones Financial Companies Lllp raised its stake in shares of ResMed by 52.6% during the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock worth $645,000 after acquiring an additional 994 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in shares of ResMed during the 2nd quarter worth approximately $389,000. Brown Advisory Inc. raised its stake in shares of ResMed by 17.8% during the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock worth $409,000 after acquiring an additional 240 shares in the last quarter. Cresset Asset Management LLC bought a new position in shares of ResMed during the 2nd quarter worth approximately $206,000. Finally, Alliancebernstein L.P. raised its stake in shares of ResMed by 24.2% during the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock worth $73,808,000 after acquiring an additional 55,790 shares in the last quarter. Institutional investors own 54.98% of the company’s stock.

ResMed Company Profile

(Get Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.